Karo Bio Strengthens Eprotirome Phase II Program With Additional Clinical Study

Karo Bio initiates the second clinical phase IIb dose ranging study with eprotirome. This study will be conducted in dyslipidemia patients receiving concomitant treatment with the cholesterol absorption inhibitor ezetimibe. The first phase IIb study in 180 patients where eprotirome is given in addition to statin treatment is progressing according to plan. Karo Bio’s compound eprotirome is a novel, selective, thyroid hormone agonist for treatment of dyslipidemia.

More: continued here

Filed under: Cholesterol on April 2nd, 2008